[Diagnosis and therapy of chronic viral hepatitis]. 1996

T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
Medizinische Klinik und Poliklinik, Klinik für Gastroenterologie und Infektiologie, Heinrich-Heine-Universität Düsseldorf.

Recent advances in our understanding of viral hepatitis involve the discovery and further characterization of the hepatitis C virus and the interferon treatment of patients with chronic viral hepatitis. Liver cirrhosis and primary hepatocellular carcinoma can develop after some years of disease. Interferon is the only effective treatment, which may improve symptoms and prognosis in some patients. Long-term responses with termination of viral replication are seen in 40% of patients with hepatitis B and 15-25% of patients with hepatitis C. In some patients complete elimination of the virus occurs. Higher response rates are achievable in subgroups of patients with favourable prognostic constellations. Patients have to be informed about side-effects and risks of interferon therapy. Treatment in uncomplicated cases is performed on an outpatient basis. The present paper reviews diagnosis, indications, contraindications and practical considerations concerning interferon treatment in patients with chronic viral hepatitis.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006525 Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). Viral Hepatitis, Human,Human Viral Hepatitides,Human Viral Hepatitis,Viral Hepatitides, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
December 1994, Immunitat und Infektion,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
March 1999, Versicherungsmedizin,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
April 1993, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
February 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
March 1991, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
February 1994, Hospital practice (Office ed.),
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
March 1996, La Clinica terapeutica,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
June 1991, The Journal of hospital infection,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
November 1994, International journal of clinical pharmacology and therapeutics,
T Heintges, and C Niederau, and L Mohr, and F Hensel, and D Häussinger
December 1999, Der Internist,
Copied contents to your clipboard!